PPA
CLYM

Parametric Portfolio Associates’s Climb Bio CLYM Stock Holding History

Parametric Portfolio Associates’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-47,191
Closed -$494K – 3776
2021
Q4 		$494K Buy
+47,191
New +$704K ﹤0.01% 3074

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Parametric Portfolio Associates's CLYM Position: Q1 2022 in Review

Parametric Portfolio Associates sold out of Climb Bio (CLYM) in Q1 2022, closing a stake of 47,191 shares — an estimated $494K sold.

Parametric Portfolio Associates first reported a position in CLYM in Q4 2021 and held it in 1 quarter. The position peaked at $494K in Q4 2021. 43 funds tracked by Wall St. Rank hold CLYM as of Q1 2022.

  • Parametric Portfolio Associates reported no remaining Climb Bio position as of Q1 2022 after selling out during the quarter.
  • Parametric Portfolio Associates sold 47,191 Climb Bio shares in Q1 2022, an estimated $494K.
  • Parametric Portfolio Associates first reported a position in Climb Bio in Q4 2021 and held it in 1 quarter.
  • Parametric Portfolio Associates's Climb Bio position peaked at $494K in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Climb Bio as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.